Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
DateTimeSourceHeadlineSymbolCompany
17/12/202423:30GlobeNewswire Inc.Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024NASDAQ:ZVRAZevra Therapeutics Inc
07/12/202409:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
07/12/202409:00GlobeNewswire Inc.Zevra Therapeutics Announces Organizational ChangesNASDAQ:ZVRAZevra Therapeutics Inc
26/11/202423:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
22/11/202408:51GlobeNewswire Inc.Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
15/11/202408:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ZVRAZevra Therapeutics Inc
15/11/202405:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ZVRAZevra Therapeutics Inc
14/11/202408:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
13/11/202408:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
13/11/202408:05GlobeNewswire Inc.Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
12/11/202408:36GlobeNewswire Inc.Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
06/11/202423:30GlobeNewswire Inc.Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13NASDAQ:ZVRAZevra Therapeutics Inc
31/10/202422:30GlobeNewswire Inc.Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024NASDAQ:ZVRAZevra Therapeutics Inc
17/10/202407:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
10/10/202422:30GlobeNewswire Inc.Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:ZVRAZevra Therapeutics Inc
10/10/202400:00GlobeNewswire Inc.NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
24/09/202421:30GlobeNewswire Inc.Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024NASDAQ:ZVRAZevra Therapeutics Inc
21/09/202406:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
21/09/202402:08GlobeNewswire Inc.Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
06/09/202422:30GlobeNewswire Inc.Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumNASDAQ:ZVRAZevra Therapeutics Inc
29/08/202421:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
14/08/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
14/08/202406:05GlobeNewswire Inc.Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:ZVRAZevra Therapeutics Inc
13/08/202419:45IH Market NewsU.S. Futures Climb Before Inflation Data; Oil Slips on OPEC Demand CutNASDAQ:ZVRAZevra Therapeutics Inc
10/08/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
10/08/202406:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVRAZevra Therapeutics Inc
09/08/202414:00GlobeNewswire Inc.Zevra Therapeutics Announces Pricing of Underwritten Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
09/08/202406:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
09/08/202406:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVRAZevra Therapeutics Inc
09/08/202406:01GlobeNewswire Inc.Zevra Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA

Your Recent History

Delayed Upgrade Clock